Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ashler et MansonXPAR:MLAEM 80 EBITDA Margin % is 20.20% as of Dec. 2024, which is 48% above its 10-year median of 13.61. GuruFocus rates XPAR:MLAEM with a GF Score™ of 80/100 and a GF Value™ of €2.62 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 372 Insurance companies, Ashler et Manson ranks better than 65.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ashler et Manson's EBITDA for the
six
months ended in Dec. 2024 was €0.08 Mil. Ashler et Manson's Revenue for the
six
months ended in Dec. 2024 was €0.41 Mil. Therefore, Ashler et Manson's EBITDA margin for the quarter that ended in Dec. 2024 was 20.20%.
Ashler et Manson (XPAR:MLAEM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ashler et Manson EBITDA Margin % Related Terms
Ashler et Manson EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ashler et Manson's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MLAEM vs MRSH, AON, AJG: EBITDA Margin % Comparison
For the Insurance Brokers subindustry, Ashler et Manson's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ashler et Manson EBITDA Margin % vs Insurance Industry
For the Insurance industry and Financial Services sector, Ashler et Manson's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ashler et Manson's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ashler et Manson (XPAR:MLAEM) has a EBITDA Margin % of 20.20% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ashler et Manson and its competitors. This is 48% above median its historical median of 13.61. According to the industry distribution chart, Ashler et Manson ranks #130 out of 372 companies in the Insurance industry, placing it in the top 34.9%.
Is Ashler et Manson's EBITDA Margin % too high?
Ashler et Manson's current EBITDA Margin % of 20.20% is 48% above median its 10-year median of 13.61. The Insurance industry median EBITDA Margin % is 14.72. Ashler et Manson's value of 20.20% is 37.3% above this industry median. Based on the distribution chart, Ashler et Manson ranks #130 out of 372 companies in the Insurance industry, which is above the industry midpoint. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's EBITDA Margin % compare to MRSH and AON?
According to the Insurance industry distribution chart, Ashler et Manson ranks #130 out of 372 companies for EBITDA Margin %. This puts Ashler et Manson in the upper half of its industry. The industry median EBITDA Margin % is 14.72. Ashler et Manson's value of 20.20% is 37.3% above this benchmark. While the company's 10-year median is 13.61 vs. the industry median of 14.72, Ashler et Manson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Insurance company?
The median EBITDA Margin % among Insurance companies is 14.72, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ashler et Manson's current EBITDA Margin % of 20.20% is 37.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ashler et Manson and its competitors. For the Insurance industry, the median EBITDA Margin % is 14.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ashler et Manson's current EBITDA Margin % is 20.20%, which is 48% above median its own 10-year median of 13.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.62, compared to a current price of €3.04 — trading 16% above its estimated fair value. The current EBITDA Margin % is 20.20%, which is 48% above median its 10-year median of 13.61 and 37.3% above the Insurance industry median of 14.72. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current EBITDA Margin % is 20.20% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?
Based on GuruFocus' analysis, Ashler et Manson stock appears to be overvalued.
The current stock price of €3.04 is trading 16% above its estimated GF Value™ of €2.62.
GuruFocus considers Ashler et Manson to be Modestly Overvalued.
Key valuation signals for XPAR:MLAEM:
EBITDA Margin %: 20.20% (48% above median its 10-year median of 13.61)
GF Value™: €2.62 vs. price of €3.04 (16% above fair value)
Industry Position: 37.3% above the Insurance median (#130 of 372)
No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLAEM has been successfully added to your 
